312 related articles for article (PubMed ID: 28415679)
1. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
3. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
4. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
5. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
6. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
7. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
[TBL] [Abstract][Full Text] [Related]
8. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
10. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
11. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
12. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K
Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172
[TBL] [Abstract][Full Text] [Related]
13. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.
Chang W; Brohl AS; Patidar R; Sindiri S; Shern JF; Wei JS; Song YK; Yohe ME; Gryder B; Zhang S; Calzone KA; Shivaprasad N; Wen X; Badgett TC; Miettinen M; Hartman KR; League-Pascual JC; Trahair TN; Widemann BC; Merchant MS; Kaplan RN; Lin JC; Khan J
Clin Cancer Res; 2016 Aug; 22(15):3810-20. PubMed ID: 26994145
[TBL] [Abstract][Full Text] [Related]
14. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
[TBL] [Abstract][Full Text] [Related]
15. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
16. Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments.
Hampel KJ; de Abreu FB; Sidiropoulos N; Peterson JD; Tsongalis GJ
Exp Mol Pathol; 2017 Apr; 102(2):215-218. PubMed ID: 28192086
[TBL] [Abstract][Full Text] [Related]
17. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
18. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.
Suehara Y; Alex D; Bowman A; Middha S; Zehir A; Chakravarty D; Wang L; Jour G; Nafa K; Hayashi T; Jungbluth AA; Frosina D; Slotkin E; Shukla N; Meyers P; Healey JH; Hameed M; Ladanyi M
Clin Cancer Res; 2019 Nov; 25(21):6346-6356. PubMed ID: 31175097
[TBL] [Abstract][Full Text] [Related]
19. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.
Shen C; Meric-Bernstam F; Su X; Mendelsohn J; Giordano S
Oncotarget; 2016 Nov; 7(44):71686-71695. PubMed ID: 27634896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
